-
Acorda Therapeutics Inc. et al v. Accord Healthcare Inc. DC
- 1:14-cv-00932
- D. Del.
- Judge: Leonard P. Stark
- Filed: 07/15/2014
- Closed: 08/18/2016
- Latest Docket Entry: 08/18/2016
- PACER
- Docket updated daily
2
Plaintiffs
2
Defendants
1
Accused
Product
5
Patents-in-Suit
766
Days in
Litigation
-
Acorda Therapeutics Inc. et al v. Accord Healthcare Inc. DC
- 1:14-cv-00932
- D. Del.
- Judge: Leonard P. Stark
- Filed: 07/15/2014
- Closed: 08/18/2016
- Latest Docket Entry: 08/18/2016
- PACER
- Docket updated daily
Cause of Action
Infringement
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
| Claim | Outcome |
|---|---|
| All challenged claims |
Enforceable and Valid
Entry 31 |
| Claim | Outcome |
|---|---|
| All challenged claims |
Enforceable and Valid
Entry 31 |
| Claim | Outcome |
|---|---|
| All challenged claims |
Enforceable and Valid
Entry 31 |
| Claim | Outcome |
|---|---|
| All challenged claims |
Enforceable and Valid
Entry 31 |
| Claim | Outcome |
|---|---|
| All challenged claims |
Enforceable and Valid
Entry 31 |
-
Infringement
Accord Healthcare Incorporated
- 5 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 10 mg dalfampridine extended release tablets | US 5,540,938 A | All Asserted Claims |
Infringement
Entry 31
|
| 10 mg dalfampridine extended release tablets | US 8,007,826 B2 | All Asserted Claims |
Infringement
Entry 31
|
| 10 mg dalfampridine extended release tablets | US 8,354,437 B2 | All Asserted Claims |
Infringement
Entry 31
|
| 10 mg dalfampridine extended release tablets | US 8,440,703 B2 | All Asserted Claims |
Infringement
Entry 31
|
| 10 mg dalfampridine extended release tablets | US 8,663,685 B2 | All Asserted Claims |
Infringement
Entry 31
|
Intas Pharmaceuticals Limited
- 5 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 10 mg dalfampridine extended release tablets | US 5,540,938 A | All Asserted Claims |
Infringement
Entry 31
|
| 10 mg dalfampridine extended release tablets | US 8,007,826 B2 | All Asserted Claims |
Infringement
Entry 31
|
| 10 mg dalfampridine extended release tablets | US 8,354,437 B2 | All Asserted Claims |
Infringement
Entry 31
|
| 10 mg dalfampridine extended release tablets | US 8,440,703 B2 | All Asserted Claims |
Infringement
Entry 31
|
| 10 mg dalfampridine extended release tablets | US 8,663,685 B2 | All Asserted Claims |
Infringement
Entry 31
|
